Back to Search
Start Over
The influence of insulin and incretin-based therapies on renal tubular transport.
- Source :
-
Journal of nephrology [J Nephrol] 2024 Nov; Vol. 37 (8), pp. 2139-2150. Date of Electronic Publication: 2024 Aug 21. - Publication Year :
- 2024
-
Abstract
- The tubular function of the kidney is very complex and is finely regulated by many factors. These include a variety of hormonal signaling pathways which are involved in the expression, activation and regulation of renal transporters responsible for the handling of electrolytes. Glucose-lowering drugs such as insulin and incretin-based therapies, exert a well-known renal protective role in diabetic kidney disease, mainly acting at the glomerular level. In the literature, several studies have described the effect of insulin and the incretin hormones on tubular transport. Most of these studies focused on the variations in excretion and clearance of sodium but did not extensively and systematically investigate the possible variations that these hormones may induce in the tubular regulation of all the other electrolytes, urea metabolism, acid-base balance and urinary pH. While insulin action on the kidney is very well-described, the renal tubular impact of incretin-based therapies is less consistent and the results available are scarce. To our knowledge, this is the first review summarizing the effects induced on renal tubules by insulin, glucagon-like peptide-1 (GLP-1) receptor agonists and serine protease dipeptidyl peptidase-4 (DPP4) inhibitors in both healthy and diabetic human subjects. This is significant because it highlights the existence of a renal-gut and pancreas axis which also has a direct tubular effect and enables a deeper understanding of renal physiology.<br />Competing Interests: Declarations. Conflict of interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. PMF received consultant fees and grant/other support from Allena Pharmaceuticals, Alnylam, Amgen, AstraZeneca, Bayer, Gilead, Novo Nordisk, Otsuka Pharmaceuticals, Rocchetta, Vifor Fresenius, and royalties as an author for UpToDate. Ethical approval: This article does not contain any studies with human participants performed by any of the authors.<br /> (© 2024. The Author(s).)
- Subjects :
- Humans
Diabetic Nephropathies drug therapy
Diabetic Nephropathies metabolism
Animals
Biological Transport
Kidney Tubules metabolism
Kidney Tubules drug effects
Incretins therapeutic use
Insulin metabolism
Glucagon-Like Peptide-1 Receptor metabolism
Dipeptidyl-Peptidase IV Inhibitors therapeutic use
Hypoglycemic Agents therapeutic use
Hypoglycemic Agents pharmacology
Glucagon-Like Peptide-1 Receptor Agonists
Subjects
Details
- Language :
- English
- ISSN :
- 1724-6059
- Volume :
- 37
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Journal of nephrology
- Publication Type :
- Academic Journal
- Accession number :
- 39167349
- Full Text :
- https://doi.org/10.1007/s40620-024-02048-w